How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

Recursion Pharmaceuticals operates as a TechBio company, using its proprietary Recursion OS to automate biological experiments and analyze them with artificial intelligence. The company generates vast ...

It's an upgrade worth making, but it comes down to your privacy concerns.

Recursion and Exscientia, two pioneers in artificial intelligence (AI)-based drug development, have completed a business combination that they vowed will enhance their ability to carry out drug ...

When AI Becomes a Self-Improving Strategic Asset The Battlefield That Exists Only in Code Imagine a commander who never sleeps, never tires, and learns from every engagement-not just from its own ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

A CONSIDERABLE gap exists between the preparation in engineering mechanics which is usually given in engineering schools and the preparation required to read such fundamental books as A. E. H. Love's ...

Your institution does not have access to this book on JSTOR. Try searching on JSTOR for other items related to this book. https://doi.org/10.2307/j.ctt2005t6j.4 https ...

Your institution does not have access to this book on JSTOR. Try searching on JSTOR for other items related to this book. Introduction: A Biosocial Approach to Global ...